TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)

Zhongming Qiu

Status and phase

Not yet enrolling

Phase 3

Phase 2

Conditions

Inflammatory Myopathy

Treatments

Drug: Telitacicept 240mg

Study type

Interventional

Funder types

Other

Identifiers

NCT07355257

2025-362

Details and patient eligibility

About

The goal of this clinical trial is to evaluate the efficacy of Telitacicept in the treatment of inflammatory myopathy in patients with inflammatory diseases. The main question it aims to answer is: the safety and effectiveness of Telitacicept in treating inflammatory myopathy.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥ 18 years and ≤ 70 years.
Patient has a confirmed diagnosis of inflammatory myopathy, meeting the 2017 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for idiopathic inflammatory myopathies.
Inadequate response or intolerance to glucocorticoids and/or at least one immunosuppressant.
The patient or their legal guardian provides written informed consent.

Exclusion criteria

Female patients who are pregnant, breastfeeding, or planning a pregnancy during the trial period.
Patients with active infections, such as herpes zoster, HIV, active tuberculosis, active hepatitis, HBsAg-positive patients, or HCV antibody-positive patients.
Patients with positive test results indicating COVID-19 infection within 1 month prior to baseline.
Patients with a history of or currently diagnosed malignancy.
Patients with significant cardiovascular diseases (including severe arrhythmia), hepatic, renal, respiratory, endocrine, or hematological disorders, or any other medical condition that, in the investigator's judgment, would interfere with participation in the study or require hospitalization during the trial.
Patients who have received intravenous immunoglobulin (IVIG) or plasmapheresis within 1 month prior to baseline.
Patients who have received other targeted biologic therapies, such as rituximab, eculizumab, tocilizumab, etc., within 3 months prior to baseline.
Patients who have received any live vaccine within 3 months prior to baseline or plan to receive any vaccine during the study period.
Patients with a known allergy to human-derived biologics.
Patients currently participating in another clinical trial.
Patients deemed unsuitable for participation by the investigator for other reasons (e.g., severe psychiatric disorders).